Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2026.1749558Case ReportA case report and literature review of duodenal adenocarcinoma with complete loss of mismatch repair proteinsAoJie1†Writing – review & editingData curationProject administrationInvestigationValidationWriting – original draftZhuXiangfeng1†Data curationInvestigationProject administrationValidationWriting – original draftZhaoYuan1ResourcesWriting – original draftZhaoMimi2ResourcesWriting – original draftLuoYi3ResourcesWriting – original draftWangQiushi1*ConceptualizationData curationFunding acquisitionProject administrationSoftwareWriting – review & editingDepartment of Pathology, Daping Hospital, Army Medical University, Chongqing, ChinaDepartment of Radiology, Daping Hospital, Army Medical University, Chongqing, ChinaDepartment of Nuclear Medicine, Daping Hospital, Army Medical University, Chongqing, ChinaCorrespondence: Qiushi Wang, wqsdpbl@tmmu.edu.cn
These authors have contributed equally to this work
Deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) phenotype holds significant prognostic and therapeutic implications in gastrointestinal cancers. While typically characterized by loss of specific MMR protein pairs, the concomitant loss of all four MMR proteins (MLH1, PMS2, MSH2, MSH6) is scarcely documented, with molecularly confirmed cases being exceptionally rare.
Case presentation
We presented a case of duodenal adenocarcinoma whose contrast-enhanced 64-row CT and PET/CT demonstrated characteristic features highly suspicious for malignancy. Subsequently, the patient underwent duodenal resection. Histopathology showed moderately differentiated adenocarcinoma invading the subserosa and immunohistochemical staining revealed MLH1, PMS2, MSH2 and MSH6 were completely lost in tumor cells. Molecular profiling confirmed MSI-H status, high tumor mutational burden (TMB-H), MLH1 promoter hypermethylation and somatic mutations in MSH2 and MSH6 genes, but without pathogenic germline variants.
Conclusion
We represent a molecularly validated case of dMMR duodenal adenocarcinoma, suggesting a somatic molecular pathogenesis distinct from classic intestinal cancer. The findings highlight the critical importance of comprehensive molecular characterization in rare tumors, as accurate identification of these phenotypes are important for optimal treatment selection, particularly immune checkpoint inhibitor therapies for gastrointestinal malignancies.
duodenal adenocarcinomahigh microsatellite instabilitymismatch repair deficiencysomatic mutationtumor mutational burdenThe author(s) declared that financial support was received for this work and/or its publication. This work was supported by Chongqing Natural Science Foundation Innovation and Development Joint Fund (grant no. CSTB2024NSCQ-LZX0043).section-at-acceptanceGastrointestinal Cancers: Colorectal CancerIntroduction
Duodenal adenocarcinoma is a rare malignancy of the small intestine, whose molecular pathogenesis is less elucidated compared to colorectal cancer (CRC) (1). A pivotal role in the molecular pathogenesis of intestinal cancers is played by defects in the DNA mismatch repair (MMR) system. The core of this system consists of protein complexes formed by MLH1, PMS2, MSH2, and MSH6, which function to identify and rectify errors occurring during DNA replication, thereby maintaining the stability of genomic microsatellite sequences (2, 3). Deficiency of MMR system (dMMR) leads to high microsatellite instability (MSI-H), which in turn drives tumorigenesis (2–4).
A strong agreement exists between MSI and MMR status (5). dMMR or MSI-H status carries significant clinical implications in CRC: such tumors often exhibit distinct pathological features, a specific clinical course, and demonstrate remarkable sensitivity to immune checkpoint inhibitors, predicting favorable treatment responses and prognosis (6).
It is noteworthy that the vast majority of intestinal cancer patients identified as dMMR show only a partial loss of protein expression (7, 8). The most common patterns are concurrent loss of MLH1 and PMS2 or concurrent loss of MSH2 and MSH6 (9). Isolated loss of a single protein is also observed. MLH1 promoter hypermethylation, while uncommon in the overall landscape of small bowel adenocarcinomas(SBAs), is a defining and important event in the majority of sporadic dMMR cases (10). However, the concurrent and complete loss of all four MMR proteins is extremely rare. Singh Aminder et al. identified 2 cases of colorectal cancer with pan-MMR loss, and compared the consistency between MMR and MSI, but the mechanism underlying the loss of all four MMR proteins has not been elucidated (11). Satoko Kageyama et al. reported a case of SBA with complete loss of all four MMR proteins, whose genetic testing revealed Lynch syndrome (LS) with a germline pathogenic variant in MSH2 (12). However, there’s no comprehensive molecular profile reported in duodenal adenocarcinoma with pan-MMR loss. A recent review emphasizes that molecular subtyping of gastrointestinal tumors is fundamental to precision medicine, enabling a shift from one-size-fits-all treatments to biomarker-driven strategies like immune checkpoint inhibitors for MSI-H/dMMR profiles and targeted therapies for specific mutations, which significantly improves outcomes for molecularly defined patient subsets (13).
Here we report a rare case of duodenal adenocarcinoma pathologically confirmed to lack all four MMR proteins in tumor cells. By detailing this case’s clinical presentation, pathological features, molecular alterations, and reviewing the relevant literature, we hope to deepen the understanding of this peculiar molecular phenotype of complete MMR protein loss, explore its potential pathogenic mechanisms.
Case presentationClinical history and imaging findings
A 57-year-old male patient presented with a one-month history of persistent abdominal distension, acid reflux, and vomiting. Physical examination revealed mild tenderness in the epigastric region without a palpable mass. Contrast-enhanced 64-row CT demonstrated localized wall thickening in the third portion (horizontal segment) of the duodenum, accompanied by luminal narrowing and heterogeneous enhancement during both arterial and portal venous phases (Figure 1A). Significant proximal duodenal dilation with fluid retention and gastric content retention was observed, suggesting high-grade intestinal obstruction. The imaging findings confirmed full-thickness invasion of the duodenal wall and involvement of the periduodenal fat plane. No evidence of distant metastasis to the liver or peritoneum was identified at the time of initial diagnosis.
Contrast-enhanced abdominal CT and PET/CT imaging of the duodenal mass. (A) CT image demonstrates circumferential wall thickening of the horizontal segment of the duodenum, showing heterogeneous enhancement; and reveals proximal duodenal and gastric dilation with fluid and content retention, indicative of high-grade obstruction. (B) PET/CT image highlights the hypermetabolic duodenal lesion and significantly increased FDG uptake within the thickened duodenal wall, highly suggestive of malignancy. (C) PET/CT shows no abnormal metabolic activity was observed in regional lymph nodes or distant metastases. CT, chest enhanced computed tomography; PET, positron-emission tomography.
Panel A shows coronal and axial abdominal CT images. Panel B presents corresponding axial and coronal PET, CT, and fused PET/CT images of the abdomen with increased tracer uptake. Panel C shows similar imaging for a different region or time point, with physiological tracer distribution in the kidneys.
PET/CT revealed abnormal bowel wall changes in the horizontal duodenum with significantly increased FDG uptake, which was highly consistent with malignant tumor characteristics based on clinical context (Figure 1B). Several small periduodenal lymph nodes were noted without increased FDG avidity (Figure 1C), suggesting reactive hyperplasia rather than metastatic involvement.
The clinical and imaging features were highly suggestive of malignant duodenal neoplasia. Subsequent histological examination of the biopsy specimens confirmed the diagnosis of adenocarcinoma. Following diagnosis, the patient underwent duodenal resection.
Histopathological diagnosis
The submitted duodenal segment measured approximately 15.3cm in length and 3.2cm in maximum diameter. An ulcerated mass was identified 2.9cm from the proximal margin and 10.5cm from the distal margin, measuring 2.2×1.8×1.1cm (Figure 2A). The mass involved the full thickness of the intestinal wall. Histopathological examination revealed a tumor (pT3N0Mx) composed of irregular glandular/tubular structures with areas showing fused and cribriform glandular patterns (Figure 2B). Focal solid/sheet-like growth patterns were observed. Tumor cells exhibited round to oval nuclei with hyperchromasia, discernible nucleoli, and frequent mitotic figures. No definite lymphovascular invasion or perineural invasion was identified.
Histopathological and immunohistochemical (IHC) findings of the duodenal adenocarcinoma. (A) Gross specimen of the resected duodenum and tumor. (B) Hematoxylin and eosin (H&E) staining reveals moderately to poorly differentiated adenocarcinoma with irregular glandular structures and stromal desmoplasia (original magnification ×250). (C-F) IHC staining for MMR proteins performed on consecutive sections of the tumor sample and results demonstrates complete loss of nuclear expression in tumor cells (blue arrows) for MLH1 (C), MSH2 (D), MSH6 (E) and PMS2 (F), with intact staining in internal controls (black arrows) (original magnification ×250).
Panel A shows a gross specimen of a resected organ, likely gastrointestinal tissue, on a grid background. Panel B presents a histology section stained with hematoxylin and eosin showing glandular structures. Panels C, D, E, and F display immunohistochemical staining of tissue sections with positive nuclear staining highlighted by arrows. Each immunohistochemistry panel shows similar glandular tissue architecture and scattered brown-stained nuclei, suggesting analysis of marker expression in a pathological sample.
Immunohistochemical staining for the MMR proteins revealed that MLH1, PMS2, MSH2 and MSH6 were completely lost in tumor cells, with preserved nuclear staining in internal control cells (Figures 2C–F), which confirmed the technical adequacy and reliability of the assay. These results indicated a dMMR status.
Molecular diagnosis
Molecular analysis further confirmed the dMMR status of the tumor. Polymerase chain reaction (PCR) and capillary electrophoresis test showed MSI-H status (Figures 3A, B). High-throughput next-generation sequencing (NGS) was performed for both tumor tissues and normal tissues, which was conducted on the Illumina high-throughput sequencing platform to analyze 556 cancer hotspot genes, using the UCSC hg19 (February 2009) human reference genome for alignment. The results identified pathogenic somatic mutations in MSH2 (p.A328fs) and MSH6 (p.T1085fs) (Table 1). No pathogenic mutations were detected in MLH1 and PMS2 genes. However, methylation-specific PCR analysis confirmed the hypermethylation on MLH1 promoter. Additionally, no mutation was found in the EPCAM, KRAS, NRAS and BRAF genes.
Molecular results of the duodenal adenocarcinoma. (A, B) Capillary electrophoresis chromatogram from microsatellite instability (MSI) testing by PCR. The tumor sample (B) demonstrates shifts in electrophoretic mobility compared to the matched blood control (A) at mononucleotide sites BAT-25 and BAT-26, and a dinucleotide D2S123 (red arrows), confirming a high level of microsatellite instability (MSI-H). (C) Next-generation sequencing (NGS) data demonstrates a high tumor mutational burden (TMB-H).
Panel A shows a multi-colored line graph representing genetic profiles for a control blood sample with several sharp peaks. Panel B displays a similar graph for tumor tissue with three blue and red arrows pointing to certain peaks indicating differences from the control. Panel C includes a shaded density plot of tumor mutational burden (TMB) with two vertical lines marking Ref=6.6 and TMB=66.4 on the x-axis.
Pathogenic variations with clinical significance detected through next-generation sequencing (NGS).
Gene
Transcript
Alteration
Mutation type
MSH2
NM_000251.1
c.983delC (p.A328fs)
Frameshift
MSH6
NM_000179.3
c.3254dupC (p.T1085fs)
Frameshift
TP53
NM_000546.5
c.C817T (p.R273C);c.C586T (p.R196*)
MissenseNonsense
PBRM1
NM_001405607.1
c.835delA (p.I279fs)
Frameshift
B2M
NM_004048.4
c.37_38del (p.L13fs)
Frameshift
DNMT3A
NM_022552.5
c.176delC (p.P59fs)
Frameshift
KMT2D
NM_003482.4
c.7061delC (p.P2354fs)
Frameshift
SOX9
NM_000346.4
c.1433dupC (p.T478fs)
Frameshift
ERBB3
NM_001982.4
c.G310A (p.V104M)
Missense
PIK3R1
NM_181523.3
c.A1699G (p.K567E)
Missense
SETD2
NM_014159.7
c.913delA (p.T305fs)
Frameshift
KMT2B
NM_014727.3
c.644delC (p.T215fs);c.A3052T (p.K1018*)
FrameshiftNonsense
ERF
NM_006494.4
c.896delG (p.G299fs)
Frameshift
RNF43
NM_017763.6
c.C1111T (p.R371*)
Nonsense
Furthermore, the genomic profiling confirmed a high tumor mutational burden (TMB-H), 66.4 mutations/Mb, extremely higher than the reference value 6.6 mutations/Mb (Figure 3C). This result was consistent with the hypermutator phenotype caused by dMMR.
Critically, comprehensive germline testing revealed no pathogenic germline variants in the MMR genes or other cancer susceptibility genes. This finding effectively rules out Lynch syndrome as the underlying cause of the MMR deficiency in this case, suggesting a purely somatic origin for the molecular alterations.
Discussion
This case presents a rare duodenal adenocarcinoma exhibiting a complete loss of all four MMR proteins. The predominant pattern of MMR deficiency in gastrointestinal cancers involves the concurrent loss of specific protein pairs due to their functional dimerization: MLH1 with PMS2, or MSH2 with MSH6. Isolated loss of PMS2 or MSH6 is also well-documented. However, the concomitant loss of all four MMR proteins is an exceptionally rare phenomenon in the literature. Reported cases are often attributed to the coincidental occurrence of two independent molecular events, such as somatic MLH1 promoter hypermethylation (causing loss of the MLH1/PMS2 pair) coupled with an incidental, potentially secondary mutation in the MSH2 or MSH6 gene (leading to loss of the MSH2/MSH6 pair) (14, 15). Fewer than 10 cases of complete MMR protein loss have been reported to date, primarily involving colorectal and small bowel cancers. The underlying mechanism mainly involves pathogenic variants in MSH genes (11, 12), and none have been reported in a molecularly validated duodenal adenocarcinoma featuring comprehensive molecular profiling.
Our case is particularly noteworthy because the IHC findings were corroborated by NGS, which identified somatic mutations in both MSH2 and MSH6, and suggested an epigenetic mechanism of MLH1 promoter hypermethylation for the loss of the MLH1/PMS2 pair. The pan-MMR deficiency in this case was driven by a “double-hit” mechanism, characterized by the combination of genetic and epigenetic disruptions. The exceptional rarity of such a complete mechanistic presentation makes this case a valuable contribution to the literature.
The MMR deficiency leads to a failure to correct errors during DNA replication, resulting in a hypermutated phenotype and MSI-H (2, 3, 16). This will contribute to a high tumor mutational burden, as was confirmed in this case. The accumulation of numerous mutations can generate neoantigens that make these tumors highly visible to the host immune system (17). While this often correlates with a prominent tumor-infiltrating lymphocyte response and the exceptional efficacy of immune checkpoint inhibitors (ICIs) in this tumor subgroup; further more indicates a more favorable prognosis (17, 18). Tumors with dMMR/MSI-H have demonstrated profound and durable responses to ICIs across multiple cancer types, leading to their FDA approval for tissue-agnostic use in advanced dMMR solid tumors (19, 20). This case represents the critical therapeutic biomarkers, indicating a high likelihood of benefit from immunotherapy, which is a pivotal consideration especially in the setting of advanced or metastatic disease where traditional chemotherapy offers limited efficacy. KRAS/NRAS wild-type status and absence of the BRAF V600E mutation suggest potential sensitivity to cetuximab and panitumumab in this case. Additionally, the NGS profiling revealed the presence of variations in several immunotherapy-related biomarkers, including three positive predictors (TP53 p.R273C; TP53 p.R196*; PBRM1 p.I279fs), two negative predictors (B2M p.L13fs; IFNGR1 p.S378fs), and one hyperprogression-associated factor (DNMT3A p.P59fs) (21, 22). Other genetic alterations (PIK3R1 p.K567E; KMT2D p.P2354fs; SOX9 p.T478fs; ERBB3 p.V104M; SETD2 p.T305fs; KMT2B p.T215fs; KMT2B p.K1018*; ERF p.G299fs; RNF43 p.R371*; RNF43 c.252 + 1G>A) associated with tumorigenesis or cancer progression were also detected (23, 24). The functional relevance of these gene variants in this particular context warrants additional investigation.
SBAs, particularly those arising in the duodenum, are uncommon neoplasms, and the prevalence of dMMR/MSI-H is lower than in colorectal cancer (20). The clinical behavior and prognosis of dMMR SBAs are not as definitively characterized as in CRC, partly due to their rarity. Some studies suggest that like in CRC, MSI-H may be associated with a better prognosis in early-stage SBA (25, 26), but this remains an area of active investigation. The true paradigm shift, however, lies in the management of advanced disease. For patients with dMMR SBA, ICIs have emerged as a transformative treatment option. Case reports and series, along with subgroup analyses of larger clinical trials, have consistently shown remarkable response rates to pembrolizumab or nivolumab in this population (19, 20). This offers a potent, often less toxic, alternative to conventional chemotherapy. The present case, with its unequivocal dMMR status, underscores the absolute necessity of routine MMR IHC or MSI testing in all patients with duodenal and small intestinal adenocarcinomas to identify those who are candidates for these potential therapies. The patient was treated with adjuvant immunotherapy (Toripalimab) for a duration of 6 months after surgery, based on the dMMR/MSI-H/TMB-H profile. The treatment was well-tolerated with no significant immune-related adverse events reported. The postoperative course has been uneventful. At the last follow-up visit (6 months post-surgery), radiographic assessment showed no evidence of local recurrence or distant metastasis. Further clinical follow-up on this patient’s treatment responses and outcomes will be essential.
Conclusion
In summary, this case report describes a rare duodenal adenocarcinoma with distinct clinicpathology and molecular features, including: 1) a rare primary location (duodenum); 2) an exceptionally rare phenotype of complete loss of all four MMR proteins; 3) MSI-H and TMB-H status, driven by a “double-hit” mechanism involving concomitant somatic mutations in the MSH2 and MSH6 genes alongside MLH1 promoter hypermethylation.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving humans were approved by Clinical Ethics Committee of Daping Hospital, Army Medical University (Chongqing, China). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
JA: Writing – review & editing, Data curation, Project administration, Investigation, Validation, Writing – original draft. XZ: Data curation, Investigation, Project administration, Validation, Writing – original draft. YZ: Resources, Writing – original draft. MZ: Resources, Writing – original draft. YL: Resources, Writing – original draft. QW: Conceptualization, Data curation, Funding acquisition, Project administration, Software, Writing – review & editing.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesAparicioTZaananASvrcekM.
Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. (2014) 46:97–104. doi: 10.1016/j.dld.2013.04.013, PMID: 23796552BolandCRGoelA.
Microsatellite instability in colorectal cancer. Gastroenterology. (2010) 138:2073–2087.e3. doi: 10.1053/j.gastro.2009.12.064, PMID: 20420947VilarEGruberSB.
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. (2010) 7:153–62. doi: 10.1038/nrclinonc.2009.237, PMID: 20142816LathamASrinivasanPKemelY.
Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J Clin Oncol. (2019) 37:286–95. doi: 10.1200/JCO.18.00283, PMID: 30376427SepulvedaARHamiltonSRAllegraCJ.
Molecular biomarkers for the evaluation of colorectal cancer: guideline from the american society for clinical pathology, college of american pathologists, association for molecular pathology, and the american society of clinical oncology. J Clin Oncol. (2017) 35:1453–86. doi: 10.1200/JCO.2016.71.9807, PMID: 28165299LeDTDurhamJNSmithKN.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. (2017) 357:409–13. doi: 10.1126/science.aan6733, PMID: 28596308HänninenUAKatainenRTanskanenT.
Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PloS Genet. (2018) 14:e1007200. doi: 10.1371/journal.pgen.1007200, PMID: 29522538BerrinoEAquilanoMCValtortaE.
Unique patterns of heterogeneous mismatch repair protein expression in colorectal cancer unveil different degrees of tumor mutational burden and distinct tumor microenvironment features. Mod Pathol. (2023) 36:100012. doi: 10.1016/j.modpat.2022.100012, PMID: 36853785WangJZhangZLiuH.
Identification of constitutional MLH1 methylation in MLH1-deficient colorectal cancer. Hum Pathol. (2025) 163:105880. doi: 10.1016/j.humpath.2025.105880, PMID: 40721001SuerinkMKilinçGTerlouwD.
Prevalence of mismatch repair deficiency and Lynch syndrome in a cohort of unselected small bowel adenocarcinomas. J Clin Pathol. (2021) 74:724–9. doi: 10.1136/jclinpath-2020-207040, PMID: 33046565AminderSSaveenaJAnkitaS.
Histopathological predictors of microsatellite instability in colorectal cancer-a tertiary care center experience. Indian J Surg Oncol. (2023) 14:137–43. doi: 10.1007/s13193-022-01633-4, PMID: 36891442KageyamaSOtaMAiharaTNakamaKIkedaJI.
Immunohistochemical “null” pattern of all four mismatch repair proteins in Lynch syndrome-associated small bowel adenocarcinoma: a case report and comprehensive genomic profiling. Virchows Arch. (2025). doi: 10.1007/s00428-025-04232-0, PMID: 40892238NomikosINKosmasCGkretsiV.
Tumor molecular signatures: bridging the bench and the operating room. Am J Surg. (2025) 246:116393. doi: 10.1016/j.amjsurg.2025.116393, PMID: 40378496AparicioTSvrcekMZaananA.
Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer. (2013) 109:3057–66. doi: 10.1038/bjc.2013.677, PMID: 24196786GonzálezIGoyalBXiaMDPaiRKMaC.
DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. Hum Pathol. (2019) 85:18–26. doi: 10.1016/j.humpath.2018.10.013, PMID: 30381262YamamotoHWatanabeYAraiHUmemotoKTateishiKSunakawaY.
Microsatellite instability: A 2024 update. Cancer Sci. (2024) 115:1738–48. doi: 10.1111/cas.16160, PMID: 38528657GaneshKStadlerZKCercekA.
Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. (2019) 16:361–75. doi: 10.1038/s41575-019-0126-x, PMID: 30886395LuchiniCBibeauFLigtenbergMJL.
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. (2019) 30:1232–43. doi: 10.1093/annonc/mdz116, PMID: 31056702ZhangXWuTCaiX.
Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol. (2022) 13:795972. doi: 10.3389/fimmu.2022.795972, PMID: 35371084WilliamsCJMPeddleAMKasiPM.
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. (2024) 21:839–51. doi: 10.1038/s41571-024-00943-6, PMID: 39317818CatalanoMIannoneLFNesiGNobiliSMiniERovielloG.
Immunotherapy-related biomarkers: Confirmations and uncertainties. Crit Rev Oncol Hematol. (2023) 192:104135. doi: 10.1016/j.critrevonc.2023.104135, PMID: 37717881PerrinoMDe VincenzoFCorduaN.
Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in Malignant mesothelioma: Work still in progress. Front Immunol. (2023) 14:1121557. doi: 10.3389/fimmu.2023.1121557, PMID: 36776840NguyenLHGoelAChungDC.
Pathways of colorectal carcinogenesis. Gastroenterology. (2020) 158:291–302. doi: 10.1053/j.gastro.2019.08.059, PMID: 31622622FeinbergAPLevchenkoA.
Epigenetics as a mediator of plasticity in cancer. Science. (2023) 379:eaaw3835. doi: 10.1126/science.aaw3835, PMID: 36758093LathamAShiaJPatelZ.
Characterization and clinical outcomes of DNA mismatch repair-deficient small bowel adenocarcinoma. Clin Cancer Res. (2021) 27:1429–37. doi: 10.1158/1078-0432.CCR-20-2892, PMID: 33199489AparicioTHenriquesJSvrcekM.
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases. Br J Cancer. (2024) 131:49–62. doi: 10.1038/s41416-024-02687-7, PMID: 38745088
Edited by: Rahul Shivahare, The Ohio State University, United States
Reviewed by: Iakovos Nomikos, METAXA Cancer Memorial Hospital, Greece
Shailesh Singh, Centre for Cellular & Molecular Biology (CCMB), India